Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25869365 | 0.86 | PLA2G2A (0.43) | CASRPOLBNPC1 | |
| SCHEMBL25869340 | 0.86 | PLA2G2A (0.43) | CASRPOLBNPC1 | |
| SCHEMBL25869603 | 0.86 | PLA2G2A (0.43) | CASRPOLBNPC1 | |
| SCHEMBL3758628 | 0.83 | CA1 (0.61) | CASRUSP2HTTCA1CA2 | |
| SCHEMBL28743806 | 0.82 | POLB (0.57) | CASRPOLBNPC1USP2HTT | |
| SCHEMBL9618015 | 0.81 | CA1 (0.62) | CASRUSP2HTTCA1CA2 | |
| SCHEMBL13609387 | 0.80 | POLB (0.57) | CASRPOLBNPC1USP2HTT | |
| SCHEMBL7171686 | 0.80 | PLA2G4B (0.60) | CASRPOLBNPC1USP2HTT | |
| SCHEMBL17683697 | 0.79 | CASR (0.62) | CASRPOLBUSP2HTTCA1 | |
| SCHEMBL25869701 | 0.79 | POLB (0.53) | POLBNPC1HTTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | CASR 4830/4885POLB 624/4885NPC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.